DexCom, Inc. (NASDAQ:DXCM) Stock Holdings Decreased by Lighthouse Investment Partners LLC

Lighthouse Investment Partners LLC reduced its position in DexCom, Inc. (NASDAQ:DXCM) by 47.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 21,773 shares of the medical device company’s stock after selling 19,327 shares during the period. Lighthouse Investment Partners LLC’s holdings in DexCom were worth $1,693,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Private Trust Co. NA grew its position in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 245 shares in the last quarter. Optiver Holding B.V. purchased a new position in DexCom during the fourth quarter valued at approximately $33,000. TD Private Client Wealth LLC grew its position in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 167 shares in the last quarter. Larson Financial Group LLC grew its position in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC purchased a new position in DexCom during the fourth quarter valued at approximately $38,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of research analyst reports. Morgan Stanley boosted their price objective on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Piper Sandler lowered their price objective on shares of DexCom from $100.00 to $90.00 and set an “overweight” rating on the stock in a research report on Friday, May 2nd. Mizuho started coverage on shares of DexCom in a research report on Thursday, April 10th. They set an “outperform” rating and a $85.00 price objective on the stock. Robert W. Baird reduced their target price on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, May 2nd. Finally, Cfra Research upgraded shares of DexCom to a “hold” rating in a research note on Friday, March 21st. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $98.11.

Insider Transactions at DexCom

In related news, CEO Kevin R. Sayer sold 32,498 shares of the company’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the transaction, the chief executive officer now directly owns 372,029 shares in the company, valued at $26,183,401.02. This represents a 8.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Jereme M. Sylvain sold 7,000 shares of the company’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $73.83, for a total transaction of $516,810.00. Following the transaction, the executive vice president now owns 135,482 shares of the company’s stock, valued at approximately $10,002,636.06. The trade was a 4.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 66,926 shares of company stock worth $4,734,384. 0.32% of the stock is owned by insiders.

DexCom Price Performance

Shares of DexCom stock opened at $84.11 on Wednesday. The firm has a fifty day simple moving average of $71.23 and a 200-day simple moving average of $77.35. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $132.26. The stock has a market capitalization of $32.98 billion, a price-to-earnings ratio of 58.82, a PEG ratio of 2.30 and a beta of 1.43.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). DexCom had a return on equity of 30.14% and a net margin of 14.29%. The firm had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same quarter in the previous year, the firm posted $0.32 earnings per share. DexCom’s quarterly revenue was up 12.5% compared to the same quarter last year. On average, sell-side analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.